Semaglutide Linked to Rare Vision Loss After Rapid 40kg Weight Drop
A 42-year-old man developed serious optic nerve damage after losing 40 kg in 2 months on Wegovy, raising ocular safety concerns.
Resumen
A case report from South Korea describes a 42-year-old man who developed nonarteritic anterior ischemic optic neuropathy (NAION) — a form of optic nerve stroke — after losing roughly 40 kg in just two months while taking semaglutide (Wegovy) for obesity. The patient had multiple vascular risk factors including diabetes, hypertension, dyslipidemia, and smoking. After discontinuing semaglutide and receiving high-dose intravenous steroids, optic disc swelling resolved over six months, but a visual field defect persisted. While a single case cannot prove causality, the report adds to growing concerns about potential ocular risks associated with semaglutide, particularly when rapid weight loss is involved.
Resumen detallado
As GLP-1 receptor agonists like semaglutide become mainstream obesity treatments, their safety profile beyond metabolic outcomes is under increasing scrutiny. Recent reports have flagged potential ocular adverse events, and this case adds a clinically important data point to that emerging concern.
Physicians in South Korea report the case of a 42-year-old man who experienced acute vision disturbance in his right eye after losing approximately 40 kg over just two months on semaglutide (Wegovy). His background included diabetes mellitus, hypertension, dyslipidemia, and a smoking history — all recognized vascular risk factors for optic nerve ischemia.
Ophthalmic examination revealed right optic disc edema with an inferior visual field defect. MRI and laboratory workup ruled out other identifiable causes of optic neuropathy, leading to a diagnosis of NAION temporally associated with semaglutide use and rapid weight reduction. Semaglutide was stopped and high-dose IV methylprednisolone was administered.
At six months follow-up, disc edema had resolved but mild optic pallor remained and the visual field defect persisted — indicating permanent structural damage. The authors hypothesize that rapid weight loss may have contributed by altering hemodynamic parameters or vascular perfusion to the optic nerve head, compounding existing vascular risk.
While a single case report cannot establish causation, it reinforces calls for heightened ophthalmologic vigilance in patients on semaglutide, especially those losing weight rapidly or carrying multiple cardiovascular risk factors. Clinicians may consider baseline eye exams and patient education about visual symptoms as a precautionary measure.
Hallazgos clave
- A 42-year-old man developed NAION after losing ~40 kg in 2 months on semaglutide (Wegovy).
- Patient had multiple vascular risk factors: diabetes, hypertension, dyslipidemia, and smoking.
- MRI and labs excluded other causes, supporting a temporal link to semaglutide and rapid weight loss.
- Treatment with IV methylprednisolone resolved disc edema, but visual field defect persisted at 6 months.
- Authors urge clinical vigilance for optic neuropathy in semaglutide users, especially with rapid weight loss.
Metodología
This is a single case report from the Department of Ophthalmology at Yeungnam University, South Korea, published in 2026. Diagnosis was supported by ophthalmic examination, visual field testing, MRI, and laboratory investigations to exclude alternative etiologies. No control group or comparative data are available.
Limitaciones del estudio
A single case report cannot establish causality between semaglutide and NAION; the patient's multiple vascular risk factors may independently explain the event. Rapid weight loss itself is a potential hemodynamic stressor that complicates attribution. The report lacks population-level incidence data to quantify absolute risk.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: